{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:42:41Z","timestamp":1791232961983,"version":"4.1.0"},"reference-count":133,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.amjcard.2006.11.016","type":"journal-article","created":{"date-parts":[[2006,12,9]],"date-time":"2006-12-09T07:14:56Z","timestamp":1165648496000},"page":"S3-S18","source":"Crossref","is-referenced-by-count":347,"special_numbering":"S1","title":["Safety Considerations with Fibrate Therapy"],"prefix":"10.1016","volume":"99","author":[{"given":"Michael H.","family":"Davidson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Armani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"McKenney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2006.11.016_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0002-9343(87)90876-X","article-title":"Potential use of fenofibrate and other fibric acid derivatives in the clinic","volume":"83","author":"Brown","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2006.11.016_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/0002-9343(87)90868-0","article-title":"Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives","volume":"83","author":"Blane","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2006.11.016_bib3","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/0140-6736(93)90625-Q","article-title":"Creatinine rise after fibrate therapy in renal graft recipients","volume":"341","author":"Devuyst","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.016_bib4","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1159\/000064083","article-title":"Fenofibrate increases creatininemia by increasing metabolic production of creatinine","volume":"92","author":"Hottelart","year":"2002","journal-title":"Nephron"},{"key":"10.1016\/j.amjcard.2006.11.016_bib5","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1592\/phco.21.13.1145.34623","article-title":"Fenofibrate-induced elevation in serum creatinine","volume":"21","author":"Ritter","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.amjcard.2006.11.016_bib6","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/ndt\/15.12.1993","article-title":"Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?","volume":"15","author":"Broeders","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjcard.2006.11.016_bib7","first-page":"39","article-title":"Deterioration in renal function associated with fibrate therapy","volume":"55","author":"Lipscombe","year":"2001","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.amjcard.2006.11.016_bib8","first-page":"273","article-title":"Fenofibrate therapy of hyperlipoproteinaemia","volume":"38","author":"Rossner","year":"1981","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2006.11.016_bib9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0021-9150(85)90121-2","article-title":"Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B","volume":"54","author":"Rouffy","year":"1985","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2006.11.016_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00007890-199405820-00018","article-title":"The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients","volume":"58","author":"Boissonnat","year":"1994","journal-title":"Transplantation"},{"key":"10.1016\/j.amjcard.2006.11.016_bib11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1365-2125.1984.tb02477.x","article-title":"The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia","volume":"18","author":"Williams","year":"1984","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.amjcard.2006.11.016_bib12","first-page":"95","article-title":"Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia","volume":"92","author":"Lageder","year":"1980","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.amjcard.2006.11.016_bib13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1185\/03007998109112364","article-title":"Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia","volume":"7","author":"Dick","year":"1981","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjcard.2006.11.016_bib14","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1159\/000189120","article-title":"Renal function changes in diabetic nephropathy induced by bezafibrate","volume":"73","author":"Bruce","year":"1996","journal-title":"Nephron"},{"key":"10.1016\/j.amjcard.2006.11.016_bib15","first-page":"140","article-title":"A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate","volume":"53","author":"Levin","year":"2000","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.amjcard.2006.11.016_bib16","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1681\/ASN.V122341","article-title":"Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease","volume":"12","author":"Deighan","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjcard.2006.11.016_bib17","series-title":"The Effect of Fenofibrate on Glomerular Filtration Rate (GFR) and Other Renal Function Tests: A Double-Blind Placebo-Controlled Cross-Over Study in Healthy Subjects","author":"Dalton","year":"2005"},{"key":"10.1016\/j.amjcard.2006.11.016_bib18","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.016_bib19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.ajkd.2004.11.004","article-title":"Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS)","volume":"45","author":"Ansquer","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjcard.2006.11.016_bib20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1517\/14740338.5.1.145","article-title":"Statin\/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions","volume":"5","author":"Davidson","year":"2006","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.amjcard.2006.11.016_bib21","first-page":"407","article-title":"Possible mechanisms of the fibrate-induced increase in serum creatinine","volume":"57","author":"Tsimihodimos","year":"2002","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.amjcard.2006.11.016_bib22","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/ndt\/16.6.1301","article-title":"Fibrate treatment can increase serum creatinine levels","volume":"16","author":"Tsimihodimos","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjcard.2006.11.016_bib23","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1210\/mend.11.6.0007","article-title":"Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay","volume":"11","author":"Krey","year":"1997","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.amjcard.2006.11.016_bib24","first-page":"41","article-title":"Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency","volume":"20","author":"Hottelart","year":"1999","journal-title":"Nephrologie"},{"key":"10.1016\/j.amjcard.2006.11.016_bib25","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1161\/01.ATV.6.6.670","article-title":"Effects of fenofibrate on plasma lipids","volume":"6","author":"Brown","year":"1986","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.amjcard.2006.11.016_bib26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0140-6736(05)77220-2","article-title":"Lipid-lowering drugs and homocysteine","volume":"353","author":"de Lorgeril","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.016_bib27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(99)02153-4","article-title":"Serum homocysteine increases after therapy with fenofibrate or bezafibrate","volume":"354","author":"Dierkes","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.016_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(00)05271-5","article-title":"Effects of fenofibrate and gemfibrozil on plasma homocysteine","volume":"358","author":"Westphal","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.016_bib29","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.016_bib30","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.016_bib31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0272-6386(04)00832-7","article-title":"Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity","volume":"44","author":"Angeles","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjcard.2006.11.016_bib32","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/ndt\/16.7.1515","article-title":"Fibrate-induced increase in blood urea and creatinine","volume":"16","author":"Lipscombe","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjcard.2006.11.016_bib33","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1523-1755.2004.00862.x","article-title":"Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency","volume":"66","author":"Tonelli","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjcard.2006.11.016_bib33a","series-title":"Mosby\u2019s Drug Consult","article-title":"Tricor [fenofibrate]","year":"2006"},{"issue":"suppl","key":"10.1016\/j.amjcard.2006.11.016_bib34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-6135.2004.0355.x","article-title":"Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative","volume":"4","author":"Kasiske","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.amjcard.2006.11.016_bib35","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/j.1552-4604.1987.tb05603.x","article-title":"The effect of renal function on the pharmacokinetics of gemfibrozil","volume":"27","author":"Evans","year":"1987","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.amjcard.2006.11.016_bib36","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.016_bib37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2362.1981.tb01839.x","article-title":"Clofibrate treatment and bile cholesterol saturation: short-term and long-term effects and influence of combination with chenodeoxycholic acid","volume":"11","author":"Angelin","year":"1981","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.amjcard.2006.11.016_bib38","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0026-0495(85)90064-2","article-title":"Effect of gemfibrozil on biliary lipid metabolism in normolipemic subjects","volume":"34","author":"Leiss","year":"1985","journal-title":"Metabolism"},{"key":"10.1016\/j.amjcard.2006.11.016_bib39","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/0021-9150(81)90008-3","article-title":"Gemfibrozil\u2014the effect of biliary cholesterol saturation of a new lipid-lowering agent and its comparison with clofibrate","volume":"39","author":"Hall","year":"1981","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2006.11.016_bib40","first-page":"213","article-title":"Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia","volume":"27","author":"Leiss","year":"1986","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2006.11.016_bib41","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2362.1984.tb02105.x","article-title":"Effect of short-term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipoproteinaemia","volume":"14","author":"von Bergmann","year":"1984","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.amjcard.2006.11.016_bib42","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1023\/A:1005643014395","article-title":"Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population","volume":"46","author":"Caroli-Bosc","year":"2001","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.amjcard.2006.11.016_bib43","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(00)04209-4","article-title":"Effect of fenofibrate on progression on coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study","volume":"357","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.016_bib44","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1161\/01.CIR.96.7.2137","article-title":"Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol","volume":"96","author":"Frick","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.016_bib45","first-page":"1069","article-title":"report from the Committee of Principal Investigators","volume":"40","year":"1978","journal-title":"Br Heart J"},{"key":"10.1016\/j.amjcard.2006.11.016_bib46","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.0954-6820.1988.tb15891.x","article-title":"Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid","volume":"223","author":"Carlson","year":"1988","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.amjcard.2006.11.016_bib47","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.016_bib48","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1161\/01.CIR.0000034044.95911.DC","article-title":"Inhibition of intestinal cholesterol absorption by ezetimibe in humans","volume":"106","author":"Sudhop","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.016_bib49","series-title":"Mosby\u2019s Drug Consult","article-title":"Zetia [ezitimibe]","year":"2006"},{"key":"10.1016\/j.amjcard.2006.11.016_bib50","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.jacc.2005.11.072","article-title":"Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia","volume":"47","author":"McKenney","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.016_bib51","first-page":"515","article-title":"Antilipemic therapy and rhabdomyolysis","volume":"144","author":"Paragh","year":"2003","journal-title":"Orv Hetil"},{"key":"10.1016\/j.amjcard.2006.11.016_bib52","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00001648-200109000-00017","article-title":"Lipid-lowering drugs and risk of myopathy: a population-based follow-up study","volume":"12","author":"Gaist","year":"2001","journal-title":"Epidemiology"},{"key":"10.1016\/j.amjcard.2006.11.016_bib53","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.016_bib54","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/pds.977","article-title":"Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy","volume":"13","author":"Chang","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.amjcard.2006.11.016_bib55","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1345\/aph.1D282","article-title":"Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy","volume":"38","author":"Layne","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.amjcard.2006.11.016_bib56","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/archinte.165.10.1154","article-title":"Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome","volume":"165","author":"Tenenbaum","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2006.11.016_bib57","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/ard.51.4.536","article-title":"Bezafibrate induced rhabdomyolysis","volume":"51","author":"Kanterewicz","year":"1992","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjcard.2006.11.016_bib58","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/ndt\/14.4.1047","article-title":"Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism","volume":"14","author":"Clouatre","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjcard.2006.11.016_bib59","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.1990.03450010075034","article-title":"Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy","volume":"264","author":"Pierce","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.016_bib60","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1056\/NEJM197703032960913","article-title":"Untoward effects of clofibrate in hemodialyzed patients","volume":"296","author":"Kijima","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.016_bib61","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2710.2001.00369.x","article-title":"Rhabdomyolysis with HMG CoA reductase inhibitors: a class effect?","volume":"26","author":"Langford","year":"2001","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.amjcard.2006.11.016_bib62","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.amjcard.2004.06.033","article-title":"Risk of adverse events with fibrates","volume":"94","author":"Alsheikh-Ali","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.016_bib63","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM200202143460721","article-title":"Cerivastatin and reports of fatal rhabdomyolysis","volume":"346","author":"Staffa","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.016_bib64","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.amjcard.2004.10.012","article-title":"Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia","volume":"95","author":"Grundy","year":"2005","journal-title":"Am J Cardiol"},{"issue":"suppl","key":"10.1016\/j.amjcard.2006.11.016_bib65","first-page":"A74","article-title":"Combination statin and fibrate therapy in type 2 diabetes: results from the Lipids in Diabetes Study","volume":"52","author":"Neil","year":"2003","journal-title":"Diabetes"},{"issue":"suppl","key":"10.1016\/j.amjcard.2006.11.016_bib66","doi-asserted-by":"crossref","first-page":"28J","DOI":"10.1016\/0002-9149(88)90004-5","article-title":"Efficacy and long-term adverse effect pattern of lovastatin","volume":"62","author":"Tobert","year":"1988","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.016_bib67","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/00007611-199705000-00018","article-title":"Rhabdomyolysis associated with simvastatin-gemfibrozil therapy","volume":"90","author":"Tal","year":"1997","journal-title":"South Med J"},{"key":"10.1016\/j.amjcard.2006.11.016_bib68","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.amjmed.2003.10.033","article-title":"Current overview of statin-induced myopathy","volume":"116","author":"Rosenson","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2006.11.016_bib69","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjcard.2004.08.076","article-title":"Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin","volume":"95","author":"Jones","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.016_bib70","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000047304","article-title":"Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations","volume":"94","author":"Oldemeyer","year":"2000","journal-title":"Cardiology"},{"key":"10.1016\/j.amjcard.2006.11.016_bib71","first-page":"663","article-title":"Biological myolysis during combined fenofibrate-pravastatin therapy","volume":"21","author":"Raimondeau","year":"1992","journal-title":"Presse Med"},{"key":"10.1016\/j.amjcard.2006.11.016_bib72","first-page":"368","article-title":"Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives","volume":"42","author":"Kamaliah","year":"2001","journal-title":"Singapore Med J"},{"key":"10.1016\/j.amjcard.2006.11.016_bib73","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1524-6175.2005.05278.x","article-title":"Fibrates in combination with statins in the management of dyslipidemia","volume":"8","author":"Jacobson","year":"2006","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.amjcard.2006.11.016_bib74","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1067\/mcp.2002.128469","article-title":"Gemfibrozil greatly increases plasma concentrations of cerivastatin","volume":"72","author":"Backman","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2006.11.016_bib75","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1067\/mcp.2000.108507","article-title":"Plasma concentrations of active simvastatin acid are increased by gemfibrozil","volume":"68","author":"Backman","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2006.11.016_bib76","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1067\/mcp.2001.115542","article-title":"Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate","volume":"69","author":"Kyrklund","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2006.11.016_bib77","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0009-9236(03)00052-3","article-title":"Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance","volume":"73","author":"Kyrklund","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2006.11.016_bib78","series-title":"Mosby\u2019s Drug Consult","article-title":"Lipitor [atorvastatin]","year":"2006"},{"key":"10.1016\/j.amjcard.2006.11.016_bib79","series-title":"Mosby\u2019s Drug Consult","article-title":"Crestor [rosuvastatin]","year":"2006"},{"issue":"suppl","key":"10.1016\/j.amjcard.2006.11.016_bib80","doi-asserted-by":"crossref","first-page":"80A","DOI":"10.1016\/S0002-9149(05)80024-4","article-title":"Pharmacokinetics of the combination of fluvastatin and gemfibrozil","volume":"76","author":"Spence","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.016_bib81","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1124\/dmd.30.11.1280","article-title":"Effects of fibrates on metabolism of statins in human hepatocytes","volume":"30","author":"Prueksaritanont","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.amjcard.2006.11.016_bib82","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1124\/jpet.301.3.1042","article-title":"Mechanistic studies on metabolic interactions between gemfibrozil and statins","volume":"301","author":"Prueksaritanont","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.amjcard.2006.11.016_bib83","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1124\/jpet.302.1.43","article-title":"Effect of albumin and cytosol on enzyme kinetics of tolbutamide hydroxylation and on inhibition of CYP2C9 by gemfibrozil in human liver microsomes","volume":"302","author":"Wang","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.amjcard.2006.11.016_bib84","first-page":"23","article-title":"Drug-induced myopathies","volume":"57","author":"Owczarek","year":"2005","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.amjcard.2006.11.016_bib85","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1345\/aph.10315","article-title":"Statin-fibrate combination therapy","volume":"35","author":"Shek","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.amjcard.2006.11.016_bib86","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/00912700022008874","article-title":"Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers","volume":"40","author":"Pan","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.amjcard.2006.11.016_bib87","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0149-2918(03)80089-9","article-title":"An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers","volume":"25","author":"Martin","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjcard.2006.11.016_bib88","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1177\/0091270004268044","article-title":"Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans","volume":"44","author":"Bergman","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.amjcard.2006.11.016_bib89","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.clinthera.2005.12.004","article-title":"An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers","volume":"28","author":"Penn","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjcard.2006.11.016_bib90","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.016_bib91","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1161\/01.str.0000034125.94759.41","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"33","author":"Pasternak","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.amjcard.2006.11.016_bib92","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/0140-6736(92)92588-7","article-title":"WHO clofibrate\/cholesterol trial: clarifications","volume":"340","author":"Heady","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.016_bib93","first-page":"379","article-title":"cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up","volume":"2","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.016_bib94","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2796.1994.tb01029.x","article-title":"The Helsinki Heart Study: an 8.5-year safety and mortality follow-up","volume":"235","author":"Huttunen","year":"1994","journal-title":"J Intern Med"},{"key":"10.1016\/j.amjcard.2006.11.016_bib95","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/07853899309147855","article-title":"Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease: an ancillary study in the Helsinki Heart Study frame population","volume":"25","author":"Frick","year":"1993","journal-title":"Ann Med"},{"key":"10.1016\/j.amjcard.2006.11.016_bib96","series-title":"Mosby\u2019s Drug Consult","article-title":"Atromid-S [clofibrate]","year":"2006"},{"key":"10.1016\/j.amjcard.2006.11.016_bib97","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/archinte.166.7.743","article-title":"Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study","volume":"166","author":"Tenkanen","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2006.11.016_bib98","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1538-7836.2005.01141.x","article-title":"Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies","volume":"3","author":"Den Heijer","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjcard.2006.11.016_bib99","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.hjr.0000131844.77058.fa","article-title":"Fibrate treatment and prevalence risk of mild hyperhomocysteinaemia in clinical coronary heart disease patients","volume":"11","author":"Mayer","year":"2004","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.amjcard.2006.11.016_bib100","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/S0140-6736(05)77189-0","article-title":"Lipid-lowering drugs and homocysteine","volume":"353","author":"Landray","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.016_bib101","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0021-9150(00)00584-0","article-title":"Fenofibrate raises plasma homocysteine levels in the fasted and fed states","volume":"155","author":"Bissonnette","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2006.11.016_bib102","doi-asserted-by":"crossref","first-page":"551","DOI":"10.5414\/CPP39551","article-title":"Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia","volume":"39","author":"Okopien","year":"2001","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2006.11.016_bib103","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1055\/s-0038-1649476","article-title":"Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia","volume":"70","author":"Branchi","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjcard.2006.11.016_bib104","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cccn.2004.06.004","article-title":"Fenofibrate inhibits thrombogenic and fibrinolytic factors expression in adipose tissue of atherosclerotic rabbits","volume":"349","author":"Zhao","year":"2004","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.amjcard.2006.11.016_bib105","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1161\/01.CIR.85.5.1888","article-title":"Direct effects of gemfibrozil on the fibrinolytic system","volume":"85","author":"Fujii","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.016_bib106","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1055\/s-0038-1649642","article-title":"Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil","volume":"70","author":"Fujii","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjcard.2006.11.016_bib107","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0049-3848(82)90292-4","article-title":"A pilot study of the effect of Gemfibrozil on some haematological parameters","volume":"26","author":"O\u2019Brien","year":"1982","journal-title":"Thromb Res"},{"key":"10.1016\/j.amjcard.2006.11.016_bib108","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1185\/03007999009111649","article-title":"Gemfibrozil in hyperlipidaemic patients with peripheral arterial disease: some undiscovered actions","volume":"12","author":"Stringer","year":"1990","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjcard.2006.11.016_bib109","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1055\/s-0038-1648481","article-title":"Gemfibrozil reduces plasma prothrombin fragment F1 + 2 concentration, a marker of coagulability, in patients with coronary heart disease","volume":"67","author":"Wilkes","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjcard.2006.11.016_bib110","first-page":"270","article-title":"Changes induced by gemfibrozil on lipidic, coagulative and fibrinolytic pattern in patients with type IV hyperlipoproteinemia","volume":"7","author":"Avellone","year":"1988","journal-title":"Int Angiol"},{"key":"10.1016\/j.amjcard.2006.11.016_bib111","first-page":"650","article-title":"Gemfibrozil efficacy vs pantetine in dyslipoproteinemic patients: a controlled study","volume":"45","author":"Agrati","year":"1989","journal-title":"Curr Ther Res"},{"key":"10.1016\/j.amjcard.2006.11.016_bib112","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/0026-0495(86)90209-X","article-title":"Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects","volume":"35","author":"Vague","year":"1986","journal-title":"Metabolism"},{"key":"10.1016\/j.amjcard.2006.11.016_bib113","first-page":"331","article-title":"Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1","volume":"13","author":"Juhan-Vague","year":"1987","journal-title":"Diabete Metab"},{"key":"10.1016\/j.amjcard.2006.11.016_bib114","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0735-1097(87)80373-X","article-title":"Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations","volume":"9","author":"Mehta","year":"1987","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.016_bib115","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1001\/jama.288.16.2015","article-title":"Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.016_bib116","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.atherosclerosis.2003.10.003","article-title":"Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis","volume":"172","author":"Syv\u00e4nne","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2006.11.016_bib117","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(05)75415-5","article-title":"Implication of fibrate therapy for homocysteine","volume":"354","author":"Jonkers","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.016_bib118","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0021-9150(00)00474-3","article-title":"Homocysteine and lipid lowering agents","volume":"154","author":"Giral","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2006.11.016_bib119","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.amjcard.2003.12.022","article-title":"Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus","volume":"93","author":"Genest","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.016_bib119a","unstructured":"Keech T. Update on fibrates: prevention of macrovascular and microvascular events in diabetes mellitus patients\u2014new insights from the FIELD Study. Presented at the American Heart Association Scientific Sessions; November 12, 2006; Chicago, Illinois."},{"key":"10.1016\/j.amjcard.2006.11.016_bib120","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(05)75417-9","article-title":"Implication of fibrate therapy for homocysteine","volume":"354","author":"Goffin","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.016_bib121","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/00005344-200403000-00017","article-title":"Fenofibrate increases homocystinemia through a PPAR\u03b1-mediated mechanism","volume":"43","author":"Luc","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.amjcard.2006.11.016_bib122","doi-asserted-by":"crossref","first-page":"363","DOI":"10.7326\/0003-4819-131-5-199909070-00008","article-title":"Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence","volume":"131","author":"Eikelboom","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2006.11.016_bib123","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0002-8703(03)00122-4","article-title":"Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine","volume":"146","author":"Melenovsky","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2006.11.016_bib124","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00228-003-0616-0","article-title":"Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration","volume":"59","author":"Mayer","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.amjcard.2006.11.016_bib125","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJMoa060900","article-title":"Homocysteine lowering with folic acid and B vitamins in vascular disease","volume":"354","author":"Lonn","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.016_bib126","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJMoa055227","article-title":"Homocysteine lowering and cardiovascular events after acute myocardial infarction","volume":"354","author":"B\u00f8naa","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.016_bib127","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.016_bib128","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1345\/aph.17310","article-title":"Interaction between fenofibrate and warfarin","volume":"32","author":"Ascah","year":"1998","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.amjcard.2006.11.016_bib129","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/cpt196781part170","article-title":"The anticoagulant response to bishydroxycoumarin","volume":"8","author":"Schrogie","year":"1967","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2006.11.016_bib130","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0006-2952(68)90166-4","article-title":"The displacement of phenylbutazone-14C and warfarin-14C from human albumin by various drugs and fatty acids","volume":"17","author":"Solomon","year":"1968","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.amjcard.2006.11.016_bib131","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/0006-2952(67)90153-0","article-title":"The effect of various drugs on the binding of warfarin-14C to human albumin","volume":"16","author":"Solomon","year":"1967","journal-title":"Biochem Pharmacol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000291490602234X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000291490602234X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T16:07:28Z","timestamp":1628179648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000291490602234X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":133,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S000291490602234X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2006.11.016","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}